Trends in Utilization of Surgical and Transcatheter Mitral Valve Repair in the United States⋆⋆
Section snippets
Disclosures
Dr. Dawn Abbott reports research grants from Abbott Vascular (area: coronary stents, no direct compensation). Dr. Azeem Latib is a consultant for Medtronic, Abbott Vascular, Ed-wards Lifesciences and Cardiovalve. Dr. Deepak L. Bhatt discloses the following relationships—Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart
References (10)
- et al.
Burden of valvular heart diseases: a population-based study
Lancet
(2006) - et al.
2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
J Am Coll Cardiol
(2014) - et al.
4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation
J Am Coll Cardiol
(2013) - et al.
Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report
J Am Coll Cardiol
(2017) - et al.
Transcatheter mitral valve therapy: the event horizon
J Thorac Cardiovasc Surg
(2016)
Cited by (7)
Current status of the treatment of degenerative mitral valve regurgitation
2021, Revista Portuguesa de CardiologiaCitation Excerpt :However, it is also indisputable that some patients with severe MR are considered unsuitable for surgery because of increased perioperative risk owing to advanced age, frailty, LV dysfunction, and comorbidities.88 This has triggered a dramatic growth in the development of novel transcatheter mitral valve technologies for repair and replacement.89 In this context, there has been increased interest in transcatheter mitral valve replacement (TMVR), because it reduces the risk of recurrent MR inherent to repair techniques.
Machine-Learning-Based In-Hospital Mortality Prediction for Transcatheter Mitral Valve Repair in the United States
2021, Cardiovascular Revascularization MedicineCitation Excerpt :With the recent expansion of TMVR indications to include patients with heart failure and moderate to severe or severe secondary MR [4], it is expected that TMVR utilization will undoubtedly become a therapeutic option for many other patients. In fact, the use of TMVR was already increasing even before the addition of this latter indication [26]. It is for this reason that the need to generate predictive models for both in-hospital mortality and heart failure rehospitalization has become critical.
How Much Tricuspid Regurgitation?: To Clip or Not to Clip
2020, Journal of the American College of CardiologyContemporary Trends and Outcomes of Percutaneous and Surgical Mitral Valve Replacement or Repair in Patients With Cancer
2020, American Journal of CardiologyCitation Excerpt :The data is publicly available and deidentified and hence exempt from IRB. The NIS was queried using ICD-9 codes for adults >18 years and cancer (Supplementary Table 1).3,5 In the present study, we used data from January 1, 2003, through September 30, 2015 for SMVP.
Trends in Inpatient Complications and Readmissions After Transcatheter or Surgical Mitral Valve Repair From 2012 to 2016
2020, JACC: Cardiovascular InterventionsPercutaneous Mitral Valve Repair in Cancer Patients with Heart Failure and Severe Mitral Regurgitation
2022, Israel Medical Association Journal
- ⋆
⋆A part of this study was presented as a moderated poster presentation at the 30th Transcatheter Cardiovascular Therapeutics meeting in San Diego, California on September 23, 2018.